154 results about "Peptide modification" patented technology

The invention relates to a mussel bionic adhesive material based on oligopeptide modified polyglutamic acid, and a preparation method and application thereof, and belongs to the field of bionic bio-based materials. The preparation method comprises the following steps: firstly, synthesizing tyrosine-containing oligopeptide through protease catalysis, and modifying the oligopeptide onto a polyglutamic acid skeleton to obtain a bionic polymer precursor; meanwhile, polyglutamic acid is modified by cysteine groups, so that a bionic high polymer material with reducibility is synthesized, and a required reducibility reaction environment is provided. The preparation method comprises the following steps: uniformly mixing the polyglutamic acid and the precursor, activating tyrosine in the precursor in a reducing environment by using tyrosinase, converting the tyrosine into dopa to finally obtain a bionic adhesive material solution, and adjusting the pH value of the solution to be close to an isoelectric point of the polyglutamic acid to realize self-assembly to form the adhesive. The adhesive prepared by the preparation method disclosed by the invention shows excellent adhesion performance and also shows good biocompatibility.

The invention provides a peptide fragment for modifying a Fe3O4 (at) Au magnetic nanoparticle and a preparation method of the Fe3O4 (at) Au magnetic nanoparticle, the peptide fragment is an alpha-peptide fragment 1 or / and a beta-peptide fragment 1, and the fragment of the peptide fragment is as shown in SEQ ID NO: 1. The method comprises the following steps: firstly, growing a layer of gold shell on the surface of Fe3O4 in situ to provide more modification sites, and then modifying PS binding peptide (PSBP) by using an Au-S bond to construct the PS NPs selective probe. The ultralow-concentration PS can be quantitatively detected only by monitoring the ultraviolet-visible absorption change of the probe. The peptide modified Fe3O4 (at) Au probe (Fe3O4 (at) Au-PSBP) has good linearity in a range of 0 to 80 pg mL <-1 >. The probe has been successfully applied to actual samples, such as bottled water, edible salt and milk. The adding standard recovery rate is 98.85%-112.10%, and the relative standard deviation (RSD) is 2.53%-13.80%. The provided Fe3O4 (at) Au-PSBP can be easily expanded to other types of NPs by simply replacing peptides, shows huge potential as a universal specific probe, and can sensitively and quickly detect low-concentration NPs in an actual sample.

A method for providing a cargo to a C-terminal end of a peptide comprises a first stage and a second stage, wherein the first stage comprises reacting the C-terminal end of the peptide with a first reactant in the presence of a first catalyst and first radiation to provide a first intermediate, wherein the first catalyst is configured to decarboxylate the C-terminal end of the peptide in the presence of the first radiation; and wherein the second stage comprises exposing the first intermediate to a second reactant.

The invention discloses a muscle-bone regeneration sustained-release preparation for targeting knee joint cartilage and a preparation process thereof, the preparation is composed of a cartilage targeting peptide modified PLGA-hyaluronic acid composite nanoparticle sustained-release carrier, an active regeneration component, a biocompatible matrix and an anti-inflammatory component, nanoparticles are prepared by a multiple emulsion solvent evaporation method, and targeting peptide is modified; the composite concentrated growth factors, stem cells and traditional Chinese medicine extracts have the functions of targeted enrichment, long-acting slow release, anti-inflammation and cartilage regeneration promotion, and can be used for knee joint cartilage defect repair.

The invention provides an engineered bacterium outer vesicle drug delivery system capable of efficiently penetrating a blood brain barrier and targeting glioblastoma as well as a preparation method and application of the engineered bacterium outer vesicle drug delivery system, and belongs to the field of drug delivery. The engineering bacteria outer vesicle drug delivery system comprises double-layer phospholipid layer vesicles BEVs, a drug delivery system and a drug delivery system, wherein the particle size of the double-layer phospholipid layer vesicles BEVs is 20 The anti-tumor drug is wrapped in the BEVs, the surface of the BEVs is modified with functional polypeptide, and the functional polypeptide is at least one of Angiopep-2 and TAT cell penetrating peptide. Animal experiments verify that the synergistic effect of the Angiopep-2 and the TAT peptide can overcome the problem of modification saturation of the Angiopep-2 peptide, and significantly improve the ability of BEVs to penetrate through BBB and target tumor tissues. Therefore, the BEVs modified by the Angiopep-2 peptide and the TAT peptide have the advantages of multi-stage targeting, high efficiency and synergy, and can effectively deliver chemotherapeutic drugs to tumor tissues.

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.

The invention provides a combined use of a hyaluronic acid-bilirubin conjugate and honokiol in preparation of a medicine for treating osteoarthritis. The invention provides a honokiol-loaded nanoparticle, which is characterized in that a hyaluronic acid-bilirubin conjugate and honokiol are used as raw materials to prepare a nanoparticle HKL-PNPs, and then the nanoparticle HKL-PNPs is modified by a mitochondrial targeting peptide to obtain the honokiol-loaded nanoparticle HKL-MPNPs. The invention also provides a bionic nanoparticle for treating bone joints. The bionic nanoparticle is prepared by wrapping the honokiol-loaded nanoparticle with an engineered cartilage cell membrane (ECM). According to the invention, cartilage cells with high expression of IL-1R2 are obtained through a gene editing method for the first time, and mitochondrial targeted nanoparticle cores loaded with Sirtuin-3 agonists are coated by cell membranes of the cells, so that the bionic nano preparation is obtained and is used for treating OA. The prepared bionic nano preparation not only can neutralize IL-1beta mediated inflammatory reaction, but also can recover Sirtuin-3 mediated mitochondrial function imbalance, so that the result of synergistic treatment of OA is achieved.

A curcumin-containing nano-drug for treating cancer, a preparation method therefor, and use thereof. The nano-drug comprises curcumin and an extracellular vesicle expressing an anti-cancer protein TRAIL, or the nano-drug comprises curcumin and a tumor-antigen binding polypeptide-modified extracellular vesicle expressing an anti-cancer protein TRAIL. The curcumin is loaded into the extracellular vesicle for combined use, such that an extremely strong synergistic effect can be generated; the anti-cancer activity of the EV-T can be significantly enhanced by means of polypeptide modification; the composite nano-drug obtained by loading the curcumin into the extracellular vesicle can solve the problem of insolubility of curcumin, thereby further improving the anti-cancer effect.

The invention discloses a methotrexate-cationic polypeptide conjugate as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. According to the conjugate, MTX and cationic polypeptide with the amino acid sequence shown as SEQ ID NO: 1 are connected through chemical bonding, the membrane binding characteristic of oligomeric lysine and the transmembrane capacity of TAT cell-penetrating peptide are creatively fused, and a polypeptide carrier system with efficient cell penetrating capacity is constructed; mTX obtains amphipathy and electropositivity through peptide fragment modification, stable nanoparticles can be spontaneously formed, and the problems of poor water solubility and instable acidity of raw material medicines are effectively improved; according to the conjugate, the accumulation efficiency of the medicine at a diseased region is remarkably improved by utilizing the targeting characteristic of the polypeptide carrier, the action time of the medicine is prolonged through a precise delivery mechanism, and meanwhile, the system toxicity is reduced. The preparation method adopts mild coupling reaction conditions, and the product is high in purity and excellent in stability; the compound is suitable for treating immune-mediated inflammatory diseases and specific malignant tumors, and provides an innovative solution thought for treating related diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to placenta targeting peptide plCSA-BP modified tetrahedral framework nucleic acid as well as a preparation method and application thereof. The placenta targeting peptide plCSA-BP is creatively combined with tFNAs to form a tFNAs / plCSA-BP compound, the compound has excellent placenta targeting property and can effectively improve the function of placenta trophoblasts, so that the treatment effect of preeclampsia is remarkably improved, a new treatment strategy is provided for the placenta diseases in the gestation period, and the placenta targeting peptide plCSA-BP has a good application prospect. The application prospect of the nano material in placental disease treatment is expanded.

The invention belongs to the technical field of biological medicines, and particularly relates to a dual-cell-penetrating peptide modified STING inhibitor-containing specific vascular endothelium targeting nanoparticle as well as a preparation method and application of the dual-cell-penetrating peptide modified STING inhibitor-containing specific vascular endothelium targeting nanoparticle. The STING inhibitor is wrapped in the lipidosome to obtain the lipidosome nano-drug, and the lipidosome is used as a drug carrier, so that the water solubility and bioavailability of the lipidosome nano-drug can be improved; meanwhile, the cell-penetrating peptide and the targeted cell-penetrating peptide are used for jointly modifying the liposome nano-drug, and the cell-penetrating peptide and the targeted cell-penetrating peptide synergistically improve the cell-penetrating performance, help the drug to penetrate through an eye barrier and target retinal vascular endothelial cells, and increase the bioavailability of the drug. Moreover, the obtained nanoparticles exist in a liquid form and can be directly used as eye drops for treating eyes with retinopathy, so that a convenient and non-invasive eye disease treatment mode can better benefit patients with retinopathy, reduce retinal angiogenesis of the patients and facilitate treatment and prognosis of diseases.

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

This invention relates to biodetection technology, disclosing a peptide-modified gold nanocluster, its preparation method, and its application in the detection of microplastics. The peptide-modified gold nanocluster comprises a gold nanocluster and a peptide LCI modified on the surface of the gold nanocluster, wherein the peptide LCI comprises an amino acid sequence as shown in SEQ ID NO: 1. The preparation method includes the following steps: providing functionalized modified gold nanoclusters; reacting the functionalized gold nanoclusters with the peptide LCI to attach the peptide LCI to the surface of the gold nanoclusters, forming the peptide-modified gold nanocluster. The microplastic detection method includes mixing the peptide-modified gold nanocluster with a test sample that may contain microplastics to obtain a detection solution, and performing colorimetric analysis or absorbance analysis on the detection solution. This gold nanocluster can specifically recognize polypropylene, exhibiting good specificity, low cost, and rapid detection of polypropylene microplastics.

The invention discloses a nuclear targeting peptide modified DNA nano-particle based on a microfluidic technology and a preparation method and application thereof, and relates to the technical field of biological medicine, a poly (beta-amino ester) cationic polymer is used as a gene delivery carrier, the gene delivery carrier comprises a microtubule related sequence MTAS and a nuclear localization signal NLS oligopeptide, the gene delivery carrier and the plasmid DNA carrying the target gene are mixed to prepare nano-particles, and the plasmid DNA carrying the target gene is uniformly dispersed in the nano-particles by adopting a microfluidic mixing process; the nuclear targeting peptide modified DNA nano-particle is ingenious in structural design, the mixing uniformity of a nano-carrier and plasmid DNA is improved by adopting a micro-fluidic mixing process, the performance of the nano-particle is further improved by optimizing dialysis conditions, potential cytotoxicity and adverse effects are reduced, and the nuclear targeting peptide modified DNA nano-particle is suitable for large-scale production. And after transduction of non-activated T cells, strong tumor killing ability and cytokine secretion can be generated.

The invention discloses periodontitis targeted sustained-release gel based on epithelial training immunization and a preparation method thereof, and relates to the technical field of biological medicine, and the preparation method comprises the following steps: modifying poloxamer, and dissolving the modified poloxamer in anhydrous acetonitrile; the preparation method comprises the following steps: dissolving RGD peptide in a PBS (Phosphate Buffer Solution), adding N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and activating to obtain an activated RGD peptide solution; adding the activated RGD peptide solution into the modified poloxamer solution, and reacting at room temperature to obtain RGD peptide modified poloxamer; the RGD peptide modified poloxamer solution is mixed with a beta-glucan solution and a TLR2 agonist solution, and the periodontitis targeted slow-release gel is obtained. The gel provided by the invention specifically targets gingival epithelial cells, reduces inflammatory response and promotes periodontal tissue regeneration, has good biocompatibility and slow release performance, and can effectively control periodontitis and prevent relapse.

The application discloses an albumin nano-drug based on HSP90 inhibitor and a preparation method and application thereof, and belongs to the technical field of medicines.The short peptide A6 is modified to human blood albumin through a connecting chain, and the human blood albumin modified by the A6 is self-assembled with geldanamycin derivative G2111 in the presence of an organic solvent, so that the G2111 is combined to the hydrophobic region of the human blood albumin through a non-covalent bond, effective loading of the G2111 is realized, the solubility of the geldanamycin derivative is improved, the drug is targetedly released into cancer cells with high expression of CD44, the targeted accumulation of the drug in tumor tissues is enhanced, damage to other normal tissues and cells caused by off-target effects of the drug is avoided, the albumin nano-drug can be simultaneously used for chemotherapy of leukemia and solid tumors, and has important practical significance.

The present disclosure provides a nanobody platform having a high affinity purification on protein A, wherein the nanobodies may incorporate diverse bioactive peptides, lipid or glycoside in its CDR1 and / or CDR3 regions. The present disclosure also provides a peptide-modified nanobody comprising non-toxic bioactive peptides and that exhibit potent anti-tumor activity. Moreover, the peptide-modified nanobody is able to be combined with other technologies, such as but not limited to bispecific antibodies and antibody-drug conjugates. Further, the present disclosure also provides production processes of the nanobodies and their use as a treatment and diagnostic agents.

The invention discloses an antibacterial peptide modified bionic nanoparticle targeting delivery system as well as a construction method and application thereof. The antibacterial peptide modified bionic nanoparticle targeting delivery system comprises a recombinant antibacterial peptide LL-37, a macrophage membrane and an enzyme cascade reaction system, the recombinant antibacterial peptide LL-37 is expressed on the macrophage cell membrane to form a macrophage cell membrane modified by the recombinant antibacterial peptide LL-37; the enzyme cascade reaction system is wrapped by the macrophage membrane modified by the recombinant antibacterial peptide LL-37, so that the bionic nanoparticle targeted delivery system modified by the antibacterial peptide is formed; wherein a Toll-like receptor 2 and a Toll-like receptor 4 are highly expressed on the surface of a macrophage cell membrane; the enzyme cascade reaction system comprises a nano enzyme with catalase-like activity and a hydrogen peroxide-producing biological enzyme. The antibacterial peptide modified bionic nanoparticle targeting delivery system disclosed by the invention can be used for treating infectious bone defects such as periodontitis, peri-implantitis, infectious fracture, osteomyelitis and the like.

The application discloses a kind of polypeptide modified long afterglow nano-complex and its preparation method and application, nano-complex, for core-shell structure, core-shell structure is composed of the core body in inside and the shell that surrounds core body, core body is long afterglow nanomaterial, shell is by polypeptide modification and modified molecule modification, and drug loaded dendritic polymer;The nano-complex of the application can realize multiscale imaging to osteoclast, through in vivo afterglow imaging and in vivo two-photon microscopic imaging, the morphology, migration and distribution of osteoclast can be more accurately analyzed, avoid photo toxicity and background interference, improve imaging sensitivity;The nano-complex of the application is loaded with osteoporosis treatment drug alendronate ALN, and treatment drug can be replaced according to actual demand, and treatment scheme is adjusted, so that the drug loading system has universality.

An isolated peptide for regulating intracellular protein degradation that includes a linker sequence fused to a C-end degron peptide and, optionally, a caging molecule bonded to the carboxyl group of a C -terminal alanine residue. Also disclosed is a method for temporal control of protein degradation that relies on fusing a protein of interest at its C- terminus to the degron peptide having a caging molecule, and a method for high-fidelity gene editing that utilizes an RNA-dependent endonuclease modified at the C -terminus with the caged isolated peptide. A fusion protein for high-fidelity gene editing is further provided.

The application provides a zwitterionic polypeptide modified paclitaxel derivative, a prodrug nanocarrier micelle and a preparation method thereof, and belongs to the field of biological medicines. The preparation method comprises the following steps: mixing a zwitterionic polypeptide containing a sulfhydryl group with 2,2'-dithiodipyridine in a polar solvent, stirring and reacting, crystallizing, and obtaining a polypeptide derivative containing a disulfide bond; and then dissolving the polypeptide derivative and a sulfhydrylated paclitaxel (PTX-SH) in a polar solvent, adding glacial acetic acid to adjust the pH, stirring and reacting, and obtaining the paclitaxel derivative. The paclitaxel derivative is used for preparing a prodrug nanocarrier micelle by loading a hydrophobic anticancer drug, the prodrug nanocarrier micelle has a long blood circulation time in the body, a high drug loading capacity, small toxic side effects, excellent glutathione response and fast on-demand controlled release characteristics, and good tumor inhibition effect.

Nanocomplex for targeted repairing of neurovascular lesion. The nanocomplex comprises a lipid, an apolipoprotein and a targeted peptide, the targeted peptide formed by covalently linking, through a bridge structure, a nanocarrier linking end and a peptide chain targeting RAGE, which specifically binds to cerebrovascular lesion site. Based on AD and the high expression of RAGE in cerebrovascular and brain parenchyma in diabetic encephalopathy, the nanocomplex, as modified by the targeted peptide, can mainly bind, in a targeted manner, to cerebrovascular endothelium by linking the targeted peptide, to repair vascular endothelial cells, promote removal of Aβ plaque near blood vessels, and repair cerebrovascular and neurovascular unit components such as microglial cells, astrocytes and neurons. Ameliorating cognitive impairment is achieved by combined repairing of multiple components and restoring cerebrovascular functions and cerebral blood flow. The nanocomplex has a disease repair effect and can carry drugs, which are delivered to cerebrovascular lesion site.

The invention provides an FSH33 peptide modified DNA tetrahedron nano delivery system as well as a preparation method and application thereof, and aims to provide a safe and efficient antioxidant nano drug and optimize the enrichment efficiency to promote ovarian aging and ovarian tissue damage repair. The system is a nano-scale nucleic acid compound composed of a tetrahedral DNA frame structure and an FSH targeting peptide. The tetrahedral DNA frame structure is a microscopic 3D stereoscopic tetrahedral structure formed by self-assembly of DNA single chains of a specific nucleic acid sequence, wherein each side extends out of a viscous end used for being connected with an FSH peptide. The research finds that the DNA tetrahedron can safely and effectively improve the ovarian endocrine function, ovarian reserve, fertility and the like of mice in a drug protection group, has no obvious toxic or side effect on all organs and tissues of the whole body, and can promote the repair of ovarian oxidative damage.

The invention discloses a stable GE11m peptide modified extracellular vesicle anti-cancer targeting nano delivery system, a preparation method and application thereof, and belongs to the technical field of biological medicine preparations, the nano delivery system comprises extracellular vesicles which can be genetically engineered by TRAIL and are derived from mammalian cells, and a stable GE11m peptide modified extracellular vesicle anti-cancer targeting nano delivery system and a stable GE11m peptide modified extracellular vesicle anti-cancer targeting nano delivery system, according to the present invention, the surface is connected with the D-type amino acid modified GE11m targeting peptide through the CP05 anchoring peptide, the amino acid sequence of the GE11m targeting peptide is YDHWYDGYTDPQNVI, and the first tyrosine, the fourth tyrosine and the seventh threonine in the GE11m peptide sequence are replaced with the D-type amino acid so as to significantly enhance the protease resistance and the serum stability of the targeting peptide.

The invention discloses a lipid nanoparticle loaded with SOX9siRNA (small interfering Ribonucleic Acid). The lipid nanoparticle is prepared from a tumor targeting carrier material and the SOX9siRNA. The tumor targeting carrier material is prepared from phospholipide-polyethylene glycol 2000 (DSPE-PEG2000-cRGDfk) modified by cRGDfK peptide, 4-(N, N-dimethylamino) butyric acid (dilinoleyl) methyl ester (DLin-MC3-DMA), distearoyl phosphatidylcholine (DSPC), dimyristoyl glycerol-polyethylene glycol 2000 (DMG-PEG2000) and cholesterol, and the preparation method of the tumor targeting carrier material is characterized in that the tumor targeting carrier material is prepared from the cRGDfK peptide modified phospholipide-polyethylene glycol 2000 (DSPE-PEG2000-cRGDfk), the 4-(N, N-dimethylamino) butyric acid (dilinoleyl) methyl ester (DLin-MC3-DMA) The prepared SOX9siRNA loaded lipid nanoparticles can be taken by colorectal cancer cells, lysosome escape is achieved, and proliferation, migration and invasion of the colorectal cancer cells are inhibited. Meanwhile, the compound also has good tumor targeting property, anti-tumor activity and safety in a colorectal cancer tumor-bearing mouse body.

The invention discloses a preparation method and application of a tumor microenvironment response type cascade targeting small activation nucleic acid nano-drug, and belongs to the technical field of biological medicines. According to the present invention, M2 type TAM targeting peptide CRVLRSGSC modified dendrimer PAMAM is adopted to jointly load small activation RNA (sa-p38, sa-TFEB) of p38 and TFEB, and acid-sensitive liposome is adopted to wrap and protect the compound (CRV-PAMAM / saRNA) to prepare the tumor microenvironment response type cascade targeting small activation nucleic acid nano-drug, and the phenotype and the metabolic mode of M2 type TAM can be reprogrammed into M1 type TAM so as to kill tumor cells, such that the tumor microenvironment response type cascade targeting small activation nucleic acid nano-drug can be used for preparing the tumor microenvironment response type cascade targeting small activation nucleic acid nano-drug, and the tumor microenvironment response type cascade targeting small activation nucleic acid nano-drug can be used for preparing the tumor microenvironment response type cascade targeting small activation nucleic acid nano-drug. And a tumor immune microenvironment is remodeled, and finally, tumor growth is inhibited and even tumors are ablated. The invention has a very wide application prospect in gene therapy and immunotherapy of cancers, hereditary diseases, infectious diseases and the like.

Provided are a polypeptide, a polypeptide-modified magnetic bead, a preparation method therefor, and a use thereof. The C terminus of the polypeptide is modified with cysteine, and the amino acid sequence of the polypeptide is selected from one or more of SEQ ID NOs: 2-4. The polypeptide-modified magnetic bead comprises a magnetic bead, a linker unit, and a polypeptide, wherein the surface of the magnetic bead is modified with hydroxyl; the C terminus of the polypeptide is modified with cysteine, and the amino acid sequence of the polypeptide is selected from one or more of SEQ ID NOs: 1-4; and the end of one side of the linker unit is connected to the surface of the magnetic bead by means of a hydrogen bond, and the end of the other side of the linker unit is connected to the C terminus of the polypeptide by means of a thioether bond. The polypeptide can bind to a specific plasma protein in a targeted manner, especially a low-abundance plasma protein. When the obtained polypeptide-modified magnetic bead is used for plasma protein detection, the binding and detection of the low-abundance protein can be realized without separating high- and low-abundance proteins in plasma. The polypeptide-modified magnetic bead has universality.

The invention discloses a pathological microenvironment self-driven precise targeting nano-robot as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing an MOF carrier; (2) preparing MOF-coated ISLamp; a CORM-401 compound, and an organic solvent; (3) preparing apoptotic cell membranes; (4) preparing an FH peptide modified apoptosis cell membrane: coupling the FH peptide with a synthetic sequence of FHKHKSPALSPV with DSPE-PEG-NHS, then mixing with apM, carrying out ultrasonic treatment, and carrying out centrifugal purification to obtain FM; (5) preparing a nano robot: MOF (at) ISLamp; the CORM-401 and the FM membrane protein are mixed, asymmetrically wrapped, extruded to pass through a membrane, and centrifuged to obtain the nano-robot. According to the designed self-driven nano-robot integrating the triple functions of self-driving, precise targeting and collaborative treatment, CORM-401-ROS reaction is used for providing active power to break through a synovial membrane barrier, targeted enrichment of core pathological cells is achieved through an engineered cell membrane, the mitochondrial function is synergistically repaired by means of ISL and CO, OA pathological circulation is blocked, and the targeted enrichment of the core pathological cells is achieved. A brand new technical scheme is provided for treatment of osteoarthritis from symptomatic remission to pathological reversion.

This invention discloses an arginine-glycine-aspartic acid (RGD) peptide-modified chiral atomically precise metal nanoclusters, their preparation, and applications. The RGD peptide-modified chiral atomically precise metal nanoclusters consist of an atomically precise metal core, a chiral RGD peptide ligand layer, and linking molecules connecting the metal core and ligand layer. The chiral regulation and targeting functions of the RGD peptide-modified chiral atomically precise metal nanoclusters synergistically enhance their targeting and penetration at the tissue and cellular levels, thereby improving their uptake efficiency. After optimization with α... v The binding constant of β3 integrin is 1.4 × 10⁻⁶. ‑6 M ‑1 RGD peptides modify the ultrasmall metal cores of chiral atomically precise metal nanoclusters, endowing them with highly efficient and rapid renal clearance properties. This invention provides a solution suitable for various α-cell tumors, arthritis, liver fibrosis, and other conditions. v RGD peptides modified with chiral atomic precision metal nanoclusters, used to treat diseases with high expression of β3 integrin, can achieve efficient enrichment at target sites for imaging.

The invention relates to an MOTS-c targeted delivery system based on an exosome derived from astragalus membranaceus and application of the MOTS-c targeted delivery system in myocardial ischemia-reperfusion injury. The preparation method comprises the following steps: preparing an exosome AExo from radix astragali from fresh radix astragali as a raw material, modifying a cardiac troponin I targeting peptide LPFFD to the surface of the AExo by using an EDC / NHS chemical cross-linking method to obtain LPFFD-AExo, and loading a mitochondrial derived small peptide MOTS-c into the LPFFD-AExo by using an ultrasonic-assisted penetration method to obtain the LPFFD-AExo-MOTS-c. According to the invention, the accurate delivery efficiency of the damaged myocardial tissue can be improved, and efficient and accurate delivery of MOTS-c to the ischemia reperfusion damaged myocardial tissue is realized, so that the ferroptosis inhibition capability of MOTS-c is obviously enhanced, the myocardial protection effect on MI / R injury is improved, and finally efficient targeted therapy on MI / R injury is realized.